Can Plasma α-Synuclein Help Us to Differentiate Parkinson's Disease from Essential Tremor?

Tremor Other Hyperkinet Mov (N Y). 2021 May 28:11:20. doi: 10.5334/tohm.600.

Abstract

Background: Studies have revealed controversial results regarding the diagnostic accuracy of plasma α-synuclein levels in patients with Parkinson's disease (PD). This study was aimed to analyze the diagnostic accuracy of plasma α-synuclein in PD versus healthy controls and patients with essential tremor (ET).

Methods: In this cross-sectional study, we included de novo (n = 19) and advanced PD patients [OFF (n = 33), and On (n = 35) states], patients with ET (n = 19), and controls (n = 35). The total plasma α-synuclein levels were determined using an ELISA sandwich method. We performed adjusted multivariate regression analysis to estimate the association of α-synuclein levels with group conditions [controls, ET, and de novo, OFF and ON-PD]. We studied the diagnostic accuracy of plasma α-synuclein using the area under the curve (AUC).

Results: The plasma α-synuclein levels were higher in controls compared to PD and ET (p < 0.0001), discriminating de novo PD from controls (AUC = 0.74, 95% CI 0.60-0.89), with a trend towards in advanced PD (OFF state) from ET (AUC = 0.69, 95% CI 0.53-0.84).

Conclusions: This is the first study examining and comparing plasma α-synuclein levels in ET vs. PD and controls. Preliminary findings suggest that plasma α-synuclein levels might help to discriminate de novo and advanced PD from controls and ET.

Keywords: Essential tremor; Parkinson’s disease; alpha-synuclein; diagnosis; plasma biomarker.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Cross-Sectional Studies
  • Essential Tremor* / diagnosis
  • Humans
  • Parkinson Disease* / diagnosis
  • alpha-Synuclein

Substances

  • Biomarkers
  • alpha-Synuclein

Grants and funding

Junta de Castilla y León is acknowledged for funding through the Biomedicine open project call (Ref. BIO/BU06/14).